Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells

Translational Research

Volumn 190, Issue , 2017, Pages 25-39.e21

  Leti, Fatjon ^a   Legendre, Christophe ^b   Still, Christopher D ^c   Chu, Xin ^c   Petrick, Anthony ^c   Gerhard, Glenn S ^d   DiStefano, Johanna K ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Geisinger Obesity Institute   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LONG UNTRANSLATED RNA; MESSENGER RNA; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNTRANSLATED RNA; CXCL5 PROTEIN, HUMAN; MALAT1 LONG NON-CODING RNA, HUMAN; TRANSCRIPTOME;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HEALTH PROGRAM; HEP-G2 CELL LINE; HEPATIC STELLATE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; ICD-9; INSULIN RESISTANCE; INSULIN SIGNALING; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MAPK SIGNALING; NONALCOHOLIC FATTY LIVER; PATIENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; RNA SEQUENCE; UPREGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

CHEMOKINE CXCL5; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; METABOLIC NETWORKS AND PATHWAYS; NON-ALCOHOLIC FATTY LIVER DISEASE; RNA, LONG NONCODING; TRANSCRIPTOME;

EID: 85034709475     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2017.09.001     Document Type: Article

References (73)

1. Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD single topic Conference. Hepatology 37 (2003), 1202–1219.
2. Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
3. Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
4. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
5. Rafiq, N., Bai, C., Fang, Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009), 234–238.
6. Wong, V.W., Wong, G.L., Choi, P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59 (2010), 969–974.
7. Campbell, P.T., Newton, C.C., Patel, A.V., Jacobs, E.J., Gapstur, S.M., Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 35 (2012), 1835–1844.
8. Porepa, L., Ray, J.G., Sanchez-Romeu, P., Booth, G.L., Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 182 (2010), E526–E531.
9. Koek, G.H., Liedorp, P.R., Bast, A., The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412 (2011), 1297–1305.
10. Jorge, A.S., Andrade, J.M., Paraiso, A.F., et al. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obes Res Clin Pract, 2016, 10.1016/j.orcp.2016.03.009.
11. Liu, W., Baker, R.D., Bhatia, T., Zhu, L., Baker, S.S., Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci 73 (2016), 1969–1987.
12. Arrese, M., Cabrera, D., Kalergis, A.M., Feldstein, A.E., Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 61 (2016), 1294–1303.
13. Heymann, F., Tacke, F., Immunology in the liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13 (2016), 88–110.
14. Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.e10.
15. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
16. Moylan, C.A., Pang, H., Dellinger, A., et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59 (2014), 471–482.
17. Teufel, A., Itzel, T., Erhart, W., et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 151 (2016), 513–525.e0.
18. Starmann, J., Falth, M., Spindelbock, W., et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One, 7, 2012, e46584.
19. Asselah, T., Bieche, I., Laurendeau, I., et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129 (2005), 2064–2075.
20. Wruck, W., Kashofer, K., Rehman, S., et al. Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data, 2, 2015, 150068.
21. Ahrens, M., Ammerpohl, O., von Schonfels, W., et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18 (2013), 296–302.
22. Murphy, W.J., Eizirik, E., Johnson, W.E., Zhang, Y.P., Ryder, O.A., O'Brien, S.J., Molecular phylogenetics and the origins of placental mammals. Nature 409 (2001), 614–618.
23. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489 (2012), 57–74.
24. Maher, B., ENCODE: the human encyclopaedia. Nature 489 (2012), 46–48.
25. Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat Rev Genet 10 (2009), 155–159.
26. Ponting, C.P., Oliver, P.L., Reik, W., Evolution and functions of long noncoding RNAs. Cell 136 (2009), 629–641.
27. Yan, B., Wang, Z., Long noncoding RNA: its physiological and pathological roles. DNA Cell Biol 31 (2012), S34–S41.
28. Moran, V.A., Perera, R.J., Khalil, A.M., Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 40 (2012), 6391–6400.
29. Nagano, T., Fraser, P., No-nonsense functions for long noncoding RNAs. Cell 145 (2011), 178–181.
30. Wang, K.C., Chang, H.Y., Molecular mechanisms of long noncoding RNAs. Mol Cell 43 (2011), 904–914.
31. He, Y., Wu, Y.T., Huang, C., et al. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta 1842 (2014), 2204–2215.
32. Yu, F., Zheng, J., Mao, Y., et al. Long non-coding RNA APTR promotes the activation of hepatic stellate cells and the progression of liver fibrosis. Biochem Biophys Res Commun 463 (2015), 679–685.
33. Yan, C., Chen, J., Chen, N., Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. Sci Rep, 6, 2016, 22640.
34. Sun, C., Liu, X., Yi, Z., et al. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. IUBMB Life 67 (2015), 847–852.
35. Konishi, H., Ichikawa, D., Yamamoto, Y., et al. Plasma level of metastasis-associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Sci 107 (2016), 149–154.
36. Luo, J.H., Ren, B., Keryanov, S., et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 44 (2006), 1012–1024.
37. Panzitt, K., Tschernatsch, M.M., Guelly, C., et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132 (2007), 330–342.
38. Wood, G.C., Chu, X., Manney, C., et al. An electronic health record-enabled obesity database. BMC Med Inform Decis Mak, 12, 2012, 45.
39. Leti, F., Malenica, I., Doshi, M., et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res 166 (2015), 304–314.
40. DiStefano, J.K., Kingsley, C., Craig Wood, G., et al. Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetol 52 (2015), 373–382.
41. Gerhard, G.S., Benotti, P., Wood, G.C., et al. Identification of novel clinical factors associated with hepatic fat accumulation in extreme obesity. J Obes, 2014, 2014, 368210.
42. Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
43. Langmead, B., Trapnell, C., Pop, M., Salzberg, S.L., Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol, 10, 2009, R25.
44. Anders, S., Pyl, P.T., Huber, W., HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31 (2015), 166–169.
45. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15, 2014, 550.
46. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a Practical and Powerful approach to Multiple testing. J R Statist Soc B 57 (1995), 289–300.
47. Wu, Y., Liu, X., Zhou, Q., et al. Silent information regulator 1 (SIRT1) ameliorates liver fibrosis via promoting activated stellate cell apoptosis and reversion. Toxicol Appl Pharmacol 289 (2015), 163–176.
48. Ward, J.H., Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58 (1963), 236–244.
49. Li, W., Turner, A., Aggarwal, P., et al. Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics, 16, 2015, 1069.
50. Tacke, F., Zimmermann, H.W., Trautwein, C., Schnabl, B., CXCL5 plasma levels decrease in patients with chronic liver disease. J Gastroenterol Hepatol 26 (2011), 523–529.
51. Xu, L., Hui, A.Y., Albanis, E., et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54 (2005), 142–151.
52. Farrell, G.C., Larter, C.Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006), S99–S112.
53. Nakamura, A., Yoneda, M., Fujita, K., et al. Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. J Diabetes Investig 2 (2011), 483–489.
54. Paradis, V., Perlemuter, G., Bonvoust, F., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 (2001), 738–744.
55. Puthanveetil, P., Chen, S., Feng, B., Gautam, A., Chakrabarti, S., Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med 19 (2015), 1418–1425.
56. Li, C., Chen, J., Zhang, K., Feng, B., Wang, R., Chen, L., Progress and Prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma. Cell Physiol Biochem 36 (2015), 423–434.
57. Arendt, B.M., Comelli, E.M., Ma, D.W., et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61 (2015), 1565–1578.
58. Yu, F., Lu, Z., Cai, J., et al. MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle 14 (2015), 3885–3896.
59. Hamirani, Y.S., Katz, R., Nasir, K., et al. Association between inflammatory markers and liver fat: the Multi-Ethnic Study of Atherosclerosis. J Clin Exp Cardiolog, 5, 2014.
60. Wobser, H., Dorn, C., Weiss, T.S., et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 19 (2009), 996–1005.
61. Colletti, L.M., Green, M., Burdick, M.D., Kunkel, S.L., Strieter, R.M., Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. Shock 10 (1998), 248–257.
62. Colletti, L.M., Kunkel, S.L., Green, M., Burdick, M., Strieter, R.M., Hepatic inflammation following 70% hepatectomy may be related to up-regulation of epithelial neutrophil activating protein-78. Shock 6 (1996), 397–402.
63. Colletti, L.M., Kunkel, S.L., Walz, A., et al. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 23 (1996), 506–514.
64. Bisset, L.R., Schmid-Grendelmeier, P., Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 11 (2005), 35–42.
65. Xia, J., Xu, X., Huang, P., He, M., Wang, X., The potential of CXCL5 as a target for liver cancer - what do we know so far?. Expert Opin Ther Targets 19 (2015), 141–146.
66. Guo, F., Guo, L., Li, Y., Zhou, Q., Li, Z., MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. Int J Clin Exp Pathol 8 (2015), 15903–15910.
67. Colletti, L.M., Green, M.E., Burdick, M.D., Strieter, R.M., The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 31 (2000), 435–445.
68. Dominguez, M., Miquel, R., Colmenero, J., et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 136 (2009), 1639–1650.
69. Karlmark, K.R., Weiskirchen, R., Zimmermann, H.W., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50 (2009), 261–274.
70. Quinn, J.J., Chang, H.Y., Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17 (2016), 47–62.
71. Liu, S.J., Nowakowski, T.J., Pollen, A.A., et al. Single-cell analysis of long non-coding RNAs in the developing human neocortex. Genome Biol, 17, 2016, 67.
72. Shalek, A.K., Satija, R., Adiconis, X., et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 498 (2013), 236–240.
73. Chiang, D.J., Pritchard, M.T., Nagy, L.E., Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300 (2011), G697–G702.